An overview of apoptosis

Coronary Artery Disease

Volumn 8, Issue 10, 1997, Pages 593-597

  Budd, Ralph C ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; AUTOIMMUNE DISEASE; CANCER GENETICS; CELL DEATH; CELL DESTRUCTION; CELL PROLIFERATION; HUMAN; LYMPHOCYTE; NEMATODE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOMATIC CELL GENETICS;

EID: 0031472988     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199710000-00002     Document Type: Short Survey

References (44)

1. Lockshin RA: Programmed cell death in an insect. Doctoral Thesis. Cambridge, MA: Harvard University, 1963.
2. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: a basic biological •• phenomenon with widespread ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257. This is the classic paper that originally brought the concept of apoptosis to the world's attention. Although more of historical interest, it is well worth examining, if only to appreciate how much of the foundation of apoptosis was formulated in this first paper. The morphological differences between apoptosis and necrosis are well formulated.
3. Ellis HM, Horvitz HR: Genetic control of programmed cell death in the •• nematode C. elegans. Cell 1986, 44:817-829. This was the first genetic description of cell death. Until publication of this paper, it was felt that apoptosis might be largely environmentally induced. This opened up an entirely new field, suggesting that genes might induce cell death in a programmed fashion.
4. Hengartner M, Horvitz HR: C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 1994, 76:665-676.
5. Cohen JJ, Duke RC, Fadok VA, Sellins KS: Apoptosis and programmed cell death in immunity. Ann Rev Immunol 1992, 10:267-293.
6. Van Houten N, Budd RC: Accelerated programmed cell death of MRL-Ipr/Ipr T Iymphocytes. J Immunol 1992, 149:2513-2517.
7. Huang L, Soldeville G, Leeker M, Flavell R, Crispe N: The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity 1994, 1:741-749.
8. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992, 119:493-498.
9. Bettina G-K, Ruttkay-Nedecky R, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995, 21:1465-1468.
10. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez-Monterry I, Castedo M, et al.: Mitochondrial control of nuclear apoptosis. J Exp Med 1996, 183:1533-1544.
11. Schatz DG, Oettinger MA, Baltimore D: The V(D)J recombination gene, RAG-1. Cell 1989, 59:1035-1048.
12. Kappler J, Roehm N, Marrack P: T cell tolerance by clonal elimination in • the thymus. Cell 1987, 49:273-280. This was the first demonstration that self-reactive lymphocytes are eliminated during development.
13. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC: Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991, 353:765-769.
14. Surh CD, Sprent J: T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994, 372:100-103.
15. Hockenberry DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SL: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993, 75:241-251.
16. Martikainen P, Kyprianou N, Isaacs JT: Effect of transforming growth factor-b1 on proliferation and death of rat prostatic cells. Endocrinology 1990, 127:2963-2968.
17. Levine B, Huang Q, Issacs JT, Reed JC, Griffin DE, Hardwick JM: Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 1993, 361:739-742.
18. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991, 351:453-456.
19. Nagata S, Golstein P: The Fas death factor. Science 1995, 267:1449-1456.
20. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178.
21. Suda T, Okazaki Y, Naito T, Yokota N, Arai S, Ozaki K, et al.: Expression of the Fas ligand in cells of the T lineage. J Immunol 1995, 154:3806-3813.
22. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role • for CD95 ligand in preventing graft rejection. Nature 1995, 377:630-632. This suggested a novel use of Fas-ligand in inducing apoptosis of any lymphocytes that might infiltrate a graft.
23. Griffith TS, Brunner T, Fletcher DG, Green DG, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270:1189-1192.
24. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al.: • Melanoma cell expression of Fas(APO-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366. Tumors can also be smart and cover themselves with Fas-ligand to protect themselves from immune elimination.
25. Chinnaiyan AM, Dixit VM: The cell-death machine. Curr Biol 1996, • 5:555-562. A very good review of the protease machinery that governs Fas-mediated apoptosis.
26. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995, 81:505-512.
27. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camois JH, Wallach D: A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
28. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al.: FLICE, a novel FADD-homolog ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signal complex. Cell 1996, 85:817-827.
29. Boldin MP, Goncharov T, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
30. Enarl M, Hug H, Nagata S: Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 1995, 375:78-80.
31. Walker NPC, Talanian RV, Brady KD, Dang LC, Bump NJ, Ferenz CR, et al.: Crystal structure of the cysteine protease interleukin-Iβ-converting enzyme: a (p20/p10)2 homodimer. Cell 1994, 78:343-352.
32. Hu S, Vincez C, Buller M, Dixit VM: A novel family of viral death effector domain-containing molecules that inhibit both CD95 and tumor necrosis factor receptor-1-induced apoptosis. J Biol Chem 1997, 272:9621-9624.
33. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, et al.: Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Natl Acad Sci USA 1997, 94:1172-1176.
34. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, • et al.: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-520. Viruses can mimic FLICE and subvert the death pathway. If viruses are duplicating a pathway, the chances are that it is very important.
35. Hu S, Vincenz C, Ni J, Gentz R, Dixit VM: I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis. J Biol Chem 1997, 372:17255-17257.
36. Korsmeyer SJ: Regulators of cell death. Trends Genet 1995, 11:101-105.
37. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
38. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: • Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317. The first demonstration that a gene regulating apoptosis might be linked to an autoimmune syndrome resembling human lupus.
39. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosis. Adv Immunol 1985, 37:269-390.
40. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S, et al.: Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996, 5:617-627.
41. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB: Fas gene mutation in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996, 335:1643-1650.
42. Tan EM: Autoimmunity in apoptosis. J Exp Med 1994, 179:1083-1086.
43. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
44. Muller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, et al.: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997, 99:403-413.